Solving the Pharma Talent Puzzle in China
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Address: Room 301,E unit, 3rd Building,Helicon Garden (Hongjialiyuan), Haidian District,Beijing 100088,China
Tel: (86-10)82050626
Formed in May 1988, the purpose of CNMA is to promote and raise the level of research, production and sales management of the Chinese OTC industry in compliance with social ethics and the relevant laws, regulations and policies.
CNMA represents the members’interests and submits policy advices to the concerned government departments on drugs’ classification, OTC research, production and sale.
CNMA also provides the members with consulting, training and information services to promote OTC technology, enhance OTC quality and ensure the consumers’ safety in using OTC products.
Another key role is to raise the knowledge and awareness about self-medication and OTC products. CNMA also organizes different activities to strengthen cooperation and contacts with international organizations, OTC associations and enterprises.
Industry Regulation and Coordination, Education
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities.…
2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how…
Shawn Leung, CEO of Chinese biotech SinoMab, discusses the”Biotech 3.0″ philosophy that characterizes the company as it strives for both scientific innovation and differentiation. He highlights SinoMab’s atopic dermatitis and…
Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert…
Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR,…
Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading…
Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses…
EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster,…
Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today…
See our Cookie Privacy Policy Here
